scholarly journals MP444TREATMENT WITH A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE DECREASES ALBUMINURIA IN OVERWEIGHT TYPE 2 DIABETIC PATIENTS

2016 ◽  
Vol 31 (suppl_1) ◽  
pp. i487-i487
Author(s):  
Tomislav Bulum ◽  
Ingrid Prkačin ◽  
Lea Duvnjak
Keyword(s):  
Receptor Agonist ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Type 2 Diabetic

scholarly journals SP474TREATMENT WITH A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST LIRAGLUTIDE DECREASES ALBUMINURIA IN OVERWEIGHT TYPE 2 DIABETIC PATIENTS

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii536-iii536
Author(s):  
Tomislav Bulum ◽  
Kristina Blaslov ◽  
Ingrid Prkačin ◽  
Karin Zibar ◽  
Lea Duvnjak
Keyword(s):  
Receptor Agonist ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Type 2 Diabetic

scholarly journals Glucagon-like peptide-1 receptor agonist versus basal insulin in type-2 diabetic patients: An efficacy and safety analysis

2020 ◽  
Vol 19 (10) ◽  
pp. 2213-2217
Author(s):  
Kaiping Lin ◽  
Qi Lv ◽  
Xiaoling Yang ◽  
Ting Lin ◽  
Min Feng ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Basal Insulin ◽  
Receptor Agonist ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Type 2 Diabetic

Purpose: To compare the effectiveness of glucagon-like peptide 1 receptor agonist with that of basal insulin in type 2 diabetes patients. Methods: Type-2 diabetes patients who were insensitive to metformin were treated with glucagon-like peptide 1 receptor agonist (GP cohort, n = 115) or basal insulin (BI cohort, n = 152) with metformin. Hemoglobin A1c (HbA1c) level and body weight were determined, and adverse effects also recorded. Results: After 16 weeks of treatment, glucagon-like peptide 1 receptor agonist did not significantly reduce HbA1c levels (7.45 ± 2.11 % vs. 7.01 ± 2.01, p = 0.107). In contrast, basal insulin significantly reduced the levels of HbA1c (7.91 ± 2.98 % vs. 7.13 ± 2.22 %, p = 0.010, q = 3.852). Glucagon-likepeptide 1 receptor agonist reduced the body weight of patients (65.25 ± 7.55 kg vs. 62.16 ± 6.15 kg, p = 0.0008, q = 5.121), unlike basal insulin (63.71 ± 6.15 vs. 62.65 ± 6.76 kg, p = 0.154). Conclusion: Glucagon-like peptide 1 receptor agonist and basal insulin + metformin produce identical effectiveness in the treatment of type-2 diabetic patients. Keywords: Glucagon-like peptide-1 receptor agonist, Glycemic control, Insulin, Metformin, Type-2 diabetes

scholarly journals Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients

2001 ◽  
Vol 86 (8) ◽  
pp. 3717-3723 ◽  
Author(s):  
Mai-Britt Toft-Nielsen ◽  
Mette B. Damholt ◽  
Sten Madsbad ◽  
Linda M. Hilsted ◽  
Thomas E. Hughes ◽  
...  
Keyword(s):  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Type 2 Diabetic

scholarly journals Orlistat Augments Postprandial Increases In Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients: Response to Horowitz et al.

Diabetes Care ◽  
2004 ◽  
Vol 27 (11) ◽  
pp. 2771-2771
Author(s):  
T. Damci ◽  
S. Yalin ◽  
H. Balci ◽  
Z. Osar ◽  
U. Korugan ◽  
...  
Keyword(s):  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document